Literature DB >> 22418883

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.

David E Kleiner1, Elizabeth M Brunt.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) results in histologically complex specific and nonspecific injury patterns. In clinical research of NAFLD, the liver biopsy evaluation provides a wealth of information on the architectural arrangement and severity of a variety of histologic changes, including steatosis, inflammation, cellular injury, and fibrosis. This information is summarized as an overall diagnostic category, such steatosis or steatohepatitis and the severity of the injury can be graded and staged. Histopathologic disease classification in NAFLD is related to but separate from evaluation of individual histologic lesions. The patient population under study may affect the prevalence of histologic findings and in particular, pediatric patients with NAFLD may show a higher prevalence of zone 1 steatosis and periportal fibrosis as compared with adult populations. For the purposes of clinical research, it is important to provide the pathologist with biopsies that are adequate to classify the disease process as well as to grade and stage the changes. A current understanding of NAFLD pathologic classification, as well as nuances of grading and staging, is presented in this review. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22418883     DOI: 10.1055/s-0032-1306421

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  120 in total

Review 1.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

2.  Liver fibrosis scores predict liver disease mortality in the United States population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2017-05-16       Impact factor: 17.425

3.  Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease.

Authors:  David E St-Jules; Corilee A Watters; Elizabeth M Brunt; Lynne R Wilkens; Rachel Novotny; Patricia Belt; Joel E Lavine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-11       Impact factor: 2.839

4.  Experimental models of non-alcoholic fatty liver disease in rats.

Authors:  Otto Kucera; Zuzana Cervinkova
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 5.  Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.

Authors:  Puneet Puri; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

6.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

7.  Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Iradj Maleki; Mahmood Reza Aminafshari; Tarang Taghvaei; Vahid Hosseini; Alireza Rafiei; Zhila Torabizadeh; Maryam Barzin; Elahe Orang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

8.  Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate.

Authors:  Sonal Josan; Kelvin Billingsley; Juan Orduna; Jae Mo Park; Richard Luong; Liqing Yu; Ralph Hurd; Adolf Pfefferbaum; Daniel Spielman; Dirk Mayer
Journal:  NMR Biomed       Date:  2015-10-16       Impact factor: 4.044

9.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Authors:  Jeffrey B Schwimmer; Joel E Lavine; Laura A Wilson; Brent A Neuschwander-Tetri; Stavra A Xanthakos; Rohit Kohli; Sarah E Barlow; Miriam B Vos; Saul J Karpen; Jean P Molleston; Peter F Whitington; Philip Rosenthal; Ajay K Jain; Karen F Murray; Elizabeth M Brunt; David E Kleiner; Mark L Van Natta; Jeanne M Clark; James Tonascia; Edward Doo
Journal:  Gastroenterology       Date:  2016-08-26       Impact factor: 22.682

Review 10.  Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue.

Authors:  Wilhelmus J Kwanten; Wim Martinet; Peter P Michielsen; Sven M Francque
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.